INTRALIPID 30% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Intralipid 30%, and what generic alternatives are available?
Intralipid 30% is a drug marketed by Fresenius and is included in one NDA.
The generic ingredient in INTRALIPID 30% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
Summary for INTRALIPID 30%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Clinical Trials: | 83 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INTRALIPID 30% at DailyMed |
Recent Clinical Trials for INTRALIPID 30%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yale University | Phase 1 |
University of Kansas Medical Center | Early Phase 1 |
Assiut University | N/A |
Pharmacology for INTRALIPID 30%
Drug Class | Lipid Emulsion |
Anatomical Therapeutic Chemical (ATC) Classes for INTRALIPID 30%
US Patents and Regulatory Information for INTRALIPID 30%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius | INTRALIPID 30% | soybean oil | INJECTABLE;INJECTION | 019942-001 | Dec 30, 1993 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |